


RECEIVED

SEP 19 2001  
Patent Docket #  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Nicholas Van Bruggen et al.  Serial No.: 09/218,481  Filed: December 22, 1998  For: VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTOAGONISTS AND USES THEREOF	Group Art Unit: 1642  Examiner: S. Ungar  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  September 7, 2001   Eileen Ly
---	---

1740  
KD  
9-28-01

AMENDMENT UNDER 37 C.F.R. §1.116

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This communication is responsive to the Office Action mailed March 9, 2001. Applicants submit concurrently herewith a Request for Continued Examination (RCE) and a request for a three-month extension along with the required fee.

Please note that the Power of Attorney for the instant application has been changed pursuant to a Revocation and Power of Attorney submitted September 21, 2000. Accordingly, please send all future communications to the undersigned attorney directly.

Please amend the application as follows and consider the remarks set forth thereafter.

**I. AMENDMENTS**

In the Claims:

Please amend claims 1 and 8 as follows:

1. (Amended) A method of reducing cerebral edema in a mammal, comprising administering to said mammal a hVEGF antagonist in an amount effective to reduce the volume of cerebral edema in the brain of the mammal, wherein said antagonist comprises an anti-hVEGF antibody.

D  
Sub  
E